CA
LKFT

Calton & Associates’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Calton & Associates’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,524
Closed -$315K – 329
2019
Q4 		$315K Buy
1,524
+31
+2% +$5.73K 0.06% 247
2019
Q3 		$228K Buy
+1,493
New +$245K 0.05% 291

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Calton & Associates's LKFT Position: Q1 2020 in Review

Calton & Associates sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2020, closing a stake of 1,524 shares — an estimated $315K sold.

Calton & Associates first reported a position in LKFT in Q3 2019 and held it in 2 quarters. The position peaked at $315K in Q4 2019. 141 funds tracked by Wall St. Rank hold LKFT as of Q1 2020.

  • Calton & Associates reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2020 after selling out during the quarter.
  • Calton & Associates sold 1,524 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2020, an estimated $315K.
  • Calton & Associates first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2019 and held it in 2 quarters.
  • Calton & Associates's Lakefront Biotherapeutics American Depositary Shares position peaked at $315K in Q4 2019.
  • 141 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2020.

Based on Calton & Associates's 13F filing for Q1 2020, filed 30 Apr 2020.